National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
Intramural
米国
引用
ジャーナル: Science / 年: 2021 タイトル: Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. 著者: Lingshu Wang / Tongqing Zhou / Yi Zhang / Eun Sung Yang / Chaim A Schramm / Wei Shi / Amarendra Pegu / Olamide K Oloniniyi / Amy R Henry / Samuel Darko / Sandeep R Narpala / Christian Hatcher ...著者: Lingshu Wang / Tongqing Zhou / Yi Zhang / Eun Sung Yang / Chaim A Schramm / Wei Shi / Amarendra Pegu / Olamide K Oloniniyi / Amy R Henry / Samuel Darko / Sandeep R Narpala / Christian Hatcher / David R Martinez / Yaroslav Tsybovsky / Emily Phung / Olubukola M Abiona / Avan Antia / Evan M Cale / Lauren A Chang / Misook Choe / Kizzmekia S Corbett / Rachel L Davis / Anthony T DiPiazza / Ingelise J Gordon / Sabrina Helmold Hait / Tandile Hermanus / Prudence Kgagudi / Farida Laboune / Kwanyee Leung / Tracy Liu / Rosemarie D Mason / Alexandra F Nazzari / Laura Novik / Sarah O'Connell / Sijy O'Dell / Adam S Olia / Stephen D Schmidt / Tyler Stephens / Christopher D Stringham / Chloe Adrienna Talana / I-Ting Teng / Danielle A Wagner / Alicia T Widge / Baoshan Zhang / Mario Roederer / Julie E Ledgerwood / Tracy J Ruckwardt / Martin R Gaudinski / Penny L Moore / Nicole A Doria-Rose / Ralph S Baric / Barney S Graham / Adrian B McDermott / Daniel C Douek / Peter D Kwong / John R Mascola / Nancy J Sullivan / John Misasi / 要旨: The emergence of highly transmissible SARS-CoV-2 variants of concern (VOCs) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. ...The emergence of highly transmissible SARS-CoV-2 variants of concern (VOCs) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants, including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, and B.1.617 VOCs. Two antibodies are ultrapotent, with subnanomolar neutralization titers [half-maximal inhibitory concentration (IC) 0.3 to 11.1 nanograms per milliliter; IC 1.5 to 34.5 nanograms per milliliter). We define the structural and functional determinants of binding for all four VOC-targeting antibodies and show that combinations of two antibodies decrease the in vitro generation of escape mutants, suggesting their potential in mitigating resistance development.
全体 : SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1
全体
名称: SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1
要素
複合体: SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1
タンパク質・ペプチド: B1-182.1 Fab heavy chain
タンパク質・ペプチド: B1-182.1 Fab light chain
タンパク質・ペプチド: Spike glycoprotein
リガンド: 2-acetamido-2-deoxy-beta-D-glucopyranose
-
超分子 #1: SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1
超分子
名称: SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: #1-#3 詳細: Complex prepared by mixing SARS-CoV-2 spike protein and Fab fragment of antibody at a molar ratio of 1:3.6.
由来(天然)
生物種: Severe acute respiratory syndrome coronavirus 2 (ウイルス)
分子量
理論値: 539.951 KDa
-
分子 #1: B1-182.1 Fab heavy chain
分子
名称: B1-182.1 Fab heavy chain / タイプ: protein_or_peptide / ID: 1 / コピー数: 1 / 光学異性体: LEVO